Pasar al contenido principal

EL DNA MITOCONDRIAL EN LA ENFERMEDAD DE ALZHEIMER FAMILIAR: FUNCION, LIBERACION Y DELECIONES EN EL DNA MITOCONDRIAL SUBYACENTES A LA NEURODEGENERACION.

PID2020-115091RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Enhanced oxidative stress-regulated by cholesterol promotes necroptosis in Alzheimer's disease

  • Abadin, Xenia
  • Dios, Cristina de
  • Roca-Agujetas, Vicente
  • Puigros Serra, Margalida
  • Claderón, Anna
  • Trullas, Ramón
  • Colell Riera, Anna
Trabajo presentado en el Global summit on Neurodegeneratice Disease Neuro, celebrado en Salamanca (España), del 21 al 24 de junio de 2022, How do neurons die in Alzheimer¿s disease (AD)? The answer is not clear. Caspases, primary effectors during apoptosis, are activated in AD brains; however, apoptotic morphology is not evident. Furthermore, the progress of the disease that lasts for decades seems incompatible with an apoptotic death program. A recent study offers compelling evidence of active necroptosis, a regulated inflammatory cell death, in post-mortem AD brains, but still, the events that trigger or regulate necroptosis in AD are not fully known. It has been reported that oxidative stress may be determinant as to whether a cell initiates necroptosis; it is, therefore, likely that mitochondrial dysfunction, observed in the early stages of AD, might favor cells to undergo necroptosis. Previous studies from our group have shown that high intracellular cholesterol levels deplete the mitochondrial pool of GSH, thus sensitizing neurons against amyloid-beta (A¿)-induced mitochondrial oxidative stress. The present study is aimed to evaluate whether cholesterol can regulate the necroptotic pathway using both APP-PSEN1 mice that overexpress SREBF2 and cholesterol-enriched SH-SY5Y cells. Methods: Cholesterol enrichment was assessed by incubating the cells with soluble cholesterol:methyl-cyclodextrin complex (50 ¿g/ml) for 1 h followed by 4 h recovery. To induce necroptosis, cells were treated for 24 h with TLQ [TNF¿ (10 ng/ml) plus the SMAC mimetic (LCL-161, 10 ¿M) and the pan-caspase inhibitor qVD-OPH (10 ¿M)]. Results: In the brains of APP-PSEN1-SREBF2 mice, we found an up-regulated expression of the necroptosis-related proteins RIPK3 and MLKL, which together with RIPK1 accumulated in the urea-soluble protein fraction, indicative of necrosome assembly. Moreover, western blot analyses of brain extracts from triple transgenic mice also showed high levels of c-FLIP, the natural inhibitor of caspase-8, further pointing to a cholesterol-regulated engagement of the necroptotic pathway. In SH-SY5Y cells, cholesterol enrichment resulted in enhanced cell death after exposure to TLQ, which was prevented by RIPK1 and RIPK3 inhibitors (Necrostatin and GSK¿872, respectively). Similar protection against TLQ-induced necroptosis was achieved when mitochondrial GSH levels were recovered by GSH ethyl ester. Intriguingly, cholesterol also regulated the intracellular localization of RIPK3 and MLKL. Confocal microscopy showed an increased presence of nuclear RIPK3 and MLKL in cholesterol-enriched cells, recently described as a requirement for the subsequent necrosome formation in the cytosol. Overall, these findings indicate that high intracellular cholesterol levels compromise neuronal viability, promoting necroptosis and subsequent necroptosis, a pro-inflammatory type of cell death, which ultimately may contribute to chronic neuroinflammation in AD., Proyectos RTI2018-095572-B-100 y PID2020-115091RB-I00 financiados por MCIN/AEI /10.13039/501100011033 y por la Unión Europea Next GenerationEU/ PRTR
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Mitochondrial DNA deletions in the cerebrospinal fluid of patients with idiopathic REM sleep behaviour disorder

  • Puigros Serra, Margalida
  • Ivars, Elia
  • Calderón, Anna
  • Martín-Ruiz, Daniel
  • Serradell, Mònica
  • Fernández Ortiga, Manel
  • Muñoz-Lopetegi, Amaia
  • Mayà, Gerard
  • Santamaria, Joan
  • Gaig, Carles
  • Colell Riera, Anna
  • Tolosa, Eduardo;
  • Iranzo, Alex
  • Trullas, Ramón
Trabajo presentado en la International Conference on Neurodegenerative Disorders, celebrada en Lisboa (Portugal), del 19 al 21 de septiembre de 2024, Background: Idiopathic REM sleep behaviour disorder (IRBD) represents the prodromal stage of Lewy body disorders (Parkinson¿s disease (PD) and dementia with Lewy bodies (DLB)) which are linked to variations in circulating cell-free mitochondrial DNA (cf-mtDNA). Here, we assessed whether altered cf-mtDNA release and integrity are already present in IRBD. Methods: We used multiplex digital PCR to quantify cf-mtDNA copies and deletion ratio in CSF and serum in a cohort of 71 subjects, including 1) 17 patients with IRBD who remained disease-free (non-converters), 2) 34 patients initially diagnosed with IRBD who developed either PD or DLB (converters), and 3) 20 age-matched controls without IRBD or Parkinsonism. In addition, we investigated whether CD9-positive extracellular vesicles (CD9-EVs) from CSF and serum samples contained cf-mtDNA. Findings: Patients with IRBD, both converters and non-converters, exhibited more cf-mtDNA with deletions in the CSF than controls. This finding was confirmed in CD9-EVs. The high levels of deleted cf-mtDNA in CSF corresponded to a significant decrease in cf-mtDNA copies in CD9-EVs in both IRBD non-converters and converters. Conversely, a significant increase in cf-mtDNA copies was found in serum and CD9-EVs from the serum of patients with IRBD who later converted to a Lewy body disorder. Interpretation: Alterations in cf-mtDNA copy number and deletion ratio known to occur in Lewy body disorders are already present in IRBD and are not a consequence of Lewy body disease conversion., suggesting that mtDNA dysfunction is a primary molecular mechanism of the pathophysiological cascade that precedes the full clinical motor and cognitive manifestation of Lewy body disorders., Funded by Michael J. Fox Foundation research grant MJFF-001111. Funded by MICIU/AEI/10.13039/501100011033 “ERDF A way of making Europe”, grants PID2020-115091RB-I00 (RT) and PID2022-143279OB-I00 (ACo). Funded by Instituto de Salud Carlos III “European Union NextGenerationEU/PRTR”, grant PMP22/00100 (RT and ACo). Funded by AGAUR/Generalitat de Catalunya, grant SGR00490 (RT and ACo). MP has an FPI fellowship, PRE2018-083297, funded by MICIU/AEI/10.13039/501100011033 “ESF Investing in your future”.